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Simple Summary: We earlier described the involvement of the TLK1>NEK1>ATR>Chk1 axis
as a key determinant of cell cycle arrest in androgen-dependent prostate cancer (PCa) cells after
androgen deprivation. We now report that the TLK1>NEK1 axis is also involved in stabilization of
yes-associated protein 1 (YAP1), the transcriptional co-activator in the Hippo pathway, presumably
facilitating reprogramming of the cells toward castration-resistant PCa (CRPC). NEK1 interacts with
YAP1 physically resulting in its phosphorylation of 6 residues, which enhance its stability and activity.
Analyses of cancer Protein Atlas and TCGA expression panels revealed a link between activated
NEK1 and YAP1 expression and several YAP transcription targets.
Abstract: Most prostate cancer (PCa) deaths result from progressive failure in standard androgen
deprivation therapy (ADT), leading to metastatic castration-resistant PCa (mCRPC); however,
the mechanism and key players leading to this are not fully understood. While studying
the role of tousled-like kinase 1 (TLK1) and never in mitosis gene A (NIMA)-related kinase 1
(NEK1) in a DNA damage response (DDR)-mediated cell cycle arrest in LNCaP cells treated
with bicalutamide, we uncovered that overexpression of wt-NEK1 resulted in a rapid conversion to
androgen-independent (AI) growth, analogous to what has been observed when YAP1 is overexpressed.
We now report that overexpression of wt-NEK1 results in accumulation of YAP1, suggesting the
existence of a TLK1>NEK1>YAP1 axis that leads to adaptation to AI growth. Further, YAP1 is
co-immunoprecipitated with NEK1. Importantly, NEK1 was able to phosphorylate YAP1 on six
residues in vitro, which we believe are important for stabilization of the protein, possibly by increasing
its interaction with transcriptional partners. In fact, knockout (KO) of NEK1 in NT1 PCa cells resulted
in a parallel decrease of YAP1 level and reduced expression of typical YAP-regulated target genes. In
terms of cancer potential implications, the expression of NEK1 and YAP1 proteins was found to be
increased and correlated in several cancers. These include PCa stages according to Gleason score, head
and neck squamous cell carcinoma, and glioblastoma, suggesting that this co-regulation is imparted
by increased YAP1 stability when NEK1 is overexpressed or activated by TLK1, and not through
transcriptional co-expression. We propose that the TLK1>NEK1>YAP1 axis is a key determinant for
cancer progression, particularly during the process of androgen-sensitive to -independent conversion
during progression to mCRPC.
Keywords: tousled-like kinase (TLK); NIMA-related kinase 1 (NEK1); yes-associated protein 1 (YAP1);
thioridazine (THD); MS-determined phosphopeptides
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1. Introduction
The founding member of the NIMA (never in mitosis gene A) family of protein kinases was
originally identified in Aspergillus nidulans as a protein kinase essential for mitosis [1], and expression
of a dominant-negative mutant of NIMA results in G2 arrest in vertebrate cells [2]. NIMA-related
kinases (NEKs) have adapted to a variety of cellular functions in addition to mitosis [3]. In human
cells, 11 NEKs were identified that are involved in several functions. For example, NEK2 is critical
for centrosome duplication [3], whereas NEK6, 7, and 9 are regulators of the mitotic spindle and
cytokinesis [4]. NEK1, NEK4, NEK8, NEK10, and NEK11 have been linked to the DNA damage
response (DDR) and DNA repair pathways as well as ciliogenesis [3]. NEK1 mediates Chk1 activation
likely by modulating the ATRIP/ATR interaction and activity [5], although this may be controversial [6].
NEK1 activity and relocalization to nuclei were reported to increase upon a variety of genotoxic
stresses [5,7]. A defect in DNA repair in NEK1-deficient cells is suggested by the persistence of Double
Strand Breaks (DSBs) after low-dose ionizing radiation (IR). NEK1-deficient cells fail to activate the
checkpoint kinases Chk1 and Chk2, and fail to arrest properly at G1/S- or G2/M-phase checkpoints
after DNA damage [8]. NEK1-deficient cells suffer major errors in mitotic chromosome segregation
and cytokinesis, and become aneuploid [9]. Genomic instability is also manifested in NEK1+/− mice,
which later in life develop lymphomas with a higher incidence than wild type littermates [9]. NEK1 is
also known to negatively regulate apoptosis by phosphorylating VDAC1, regulating the closure of the
anion channel of the mitochondrial membrane, which promotes survival of renal cell carcinoma [10–12].
Loss of function mutation of NEK1 leads to DNA damage accumulation in the motorneurons that
may lead to several neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) [13,14].
NEK1 is associated with primary cilia and centrosomes [15,16], which was reported to be implicated in
the development of polycystic kidney disease (PKD) when there is a NEK1 deficiency [17]. However,
the precise mechanism leading to PKD due to NEK1 insufficiency is not clear, but a clue came from
the discovery that NEK1 interacts with and phosphorylates TAZ, involved in the E3 ligase complex,
which regulates the stability of polycystin 2 [18]. TAZ is also a paralog of yes-associated protein (YAP),
a transcriptional coactivator that mediates many functions in normal development and in disease
pathology, such as cancer progression, including prostate cancer [19–22].
We recently uncovered a new DDR axis involving the protein kinase tousled-like kinase (TLK)1
as an early mediator of the DDR. TLK1 serves as an upstream activator of NEK1>ATR>Chk1 [6,23],
which has important implications during the early stages of prostate cancer (PCa) progression to
androgen independence (AI) [24,25]. We found that overexpression of wt-NEK1 (but not the T141A
kinase-hypoactive mutant that cannot be phosphorylated by TLK1) hastens the progression of LNCaP
cells to androgen-independent growth [24]. The protective cell cycle arrest mediated by the TLK1>NEK1
DDR pathway seems insufficient to explain the rapid growth recovery observed in bicalutamide-treated
cells when NEK1 is overexpressed, and suggests that NEK1 may have additional functions. We
suspected that it may regulate the Hippo pathway, as it was reported that ectopic expression of YAP is
sufficient to convert LNCaP cells from androgen-sensitive (AS) to AI in vitro [19]. NEK1 was also found
to phosphorylate TAZ specifically at S309 [18], and this was related to increased CTGF expression (one
of TAZ/YAP transcriptional targets). TLKs may regulate the Hippo pathway through their activity on
NEK1 upstream of YAP/TAZ. YAP/TAZ (60% identical) are the main effectors of the Hippo signaling
pathway. This pathway is involved in regulating organ size through controlling multiple cellular
functions including cell proliferation and apoptosis [26]. The Hippo pathway responds to a variety
of signals, including cell–cell contact, mechano-transduction [21], and apico–basal polarity [20,26].
When the Hippo pathway is activated, kinases MST1/2 and LATS1/2 phosphorylate and inactivate
YAP and TAZ. YAP and TAZ are transcriptional co-activators but lack DNA binding activity. Upon
phosphorylation by MST and LATS kinases, they are sequestered in the cytoplasm, ubiquitylated by
the β-TrCP ubiquitin ligase, and marked for proteasomal degradation (reviewed in [20]). YAP/TAZ are
usually inhibited by cell–cell contact in normal tissues [26], while over-activation of YAP/TAZ through
aberrant regulation of the Hippo pathway has been noted in many types of tumors. This is associated
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with the acquisition of malignant traits, including resistance to anticancer therapies; maintenance
of cancer stem cells; distant metastasis [26]; and, in prostate, adenocarcinoma progression [27,28].
When the Hippo core kinases are “off”, YAP/TAZ translocate into the nucleus, binds to TEAD1–4, and
activates the transcription of TEAD downstream target genes, leading to multiple oncogenic activities,
including loss of contact inhibition, cell proliferation, epithelial–mesenchymal transition, and resistance
to apoptosis. In PCa, YAP has been identified as an Androgen Receptor-binding partner that colocalizes
with AR in both androgen-dependent and androgen-independent manners in castration-resistant PCa
(CRPC) patients [27]. YAP is also found to be upregulated in AI-LNCaP-C4-2 cells and, when expressed
ectopically in LNCaP cells, it activates AR signaling and confers castration resistance. Knockdown
of YAP greatly reduces the rates of migration and invasion of LNCaP, and YAP-activated androgen
receptor signaling is sufficient to promote LNCaP cells from an AS to an AI state in vitro, while
YAP conferred castration resistance in vivo [19]. It was also recently determined that ERG (and the
common TMPRSS2–ERG fusion) activates the transcriptional program regulated by YAP1, and that
prostate-specific activation of either ERG or YAP1 in mice induces similar transcriptional changes and
results in age-related prostate tumors [29]. However, it has remained unclear as to what the upstream
activators of the Hippo pathway are in PCa, and we show in this report that TLKs have a role in this
process via activation and induced stabilization of YAP from elevated phosphorylation by NEK1.
2. Materials and Methods
2.1. Plasmids and Antibodies
Wild type human full length NEK1 mammalian expression plasmid was purchased from
Origene (MR216282). NEK1 T141A variant was generated by site-directed mutagenesis, as previously
described [23]. Generation of His-tagged N-terminal NEK1 (aa 1–480) bacterial expression plasmid
was conducted as previously described. Human full length MK5 bacterial expression plasmid was
purchased from Vector Builder. The following antibodies were used in this study: mouse anti-YAP
(Santa Cruz Biotechnology, SCBT, Dallas, TX, USA, cat# sc101199), rabbit anti-phospho-YAP (Cell
Signaling Technology, CST, Dallas, TX, USA, cat# 13008), mouse anti-NEK1 (SCBT, cat# sc 398813,
Dallas, TX, USA), rabbit anti-phospho-NEK1 pT141 (lab-generated), rabbit anti-phospho-tyrosine (CST,
cat# 8954S, Dallas, TX, USA), HRP-conjugated anti-β-tubulin (SCBT, Dallas, TX, USA, cat# sc-23949),
mouse IgG (SCBT, Dallas, TX, USA, cat# sc-2025), and rabbit anti-actin (Abcam, Cambridge, MA, USA,
cat# ab1801).
2.2. Cell Culture
Human embryonic kidney HEK293 and HeLa cells were cultured in Dulbecco Modified Eagle
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin.
HEK293T cells were cultured in D10 medium containing 10% FBS, 0.25% penicillin/streptomycin,
and 1% glutamine in DMEM media. LNCaP cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. NT1 cells were a kind gift
from Dr. Xiuping Yu (Department of Biochemistry, Louisiana State University Health Sciences Center
Shreveport) and cultured according to the published literature [30]. All other cells were purchased from
American Type Culture Collection (ATCC). All the cells were maintained in a humidified incubator at
37 ◦ C with 5% CO2 .
2.3. Cell Treatment
LNCaP or HeLa or NT1 cells were plated as 5 × 105 cells per well in a 6-well plate and grown
until 70–80% confluency. Cells were treated with either 10 µM of either bicalutamide (Selleckchem,
Houston, TX, USA, cat# S1190), thioridazine (THD; Sigma Aldrich, St. Louis, MO, USA, cat# T9025 or
J54 [31], or in combination with both bicalutamide and THD for 24 h. After the treatment, cells were
harvested for Western blotting (WB) analysis or qPCR analysis.
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2.4. Cell Transfection
LNCaP cells were transfected with either wild type mouse full-length NEK1 or NEK1 T141A
variant, as previously described [23]. TLK1 shRNA (ATTACTTCATCTGCTTGGTAGAGGTGGCT)
was obtained from origene (Rockville, MD, USA, cat# TR320623). HeLa cells were plated as 105 cells
per well in a 6-well plate 24 h before shRNA transfection. Transfection was conducted using 140 nM
and 280 nM of TLK1 shRNA by lipofectamine 3000 (Thermo Scientific, Waltham, MA, USA, cat#
L3000-015) reagent for 24 h, following the manufacturer’s protocol, and subsequently selected the
cells with 1 µg/mL of puromycin for 7 days. Puromycin-selected cells were harvested and knockdown
efficiency was determined by WB.
2.5. Co-immunoprecipitation (co-IP)
Cells were lysed by sonication in 1X RIPA lysis buffer (SCBT, Dallas, TX, USA, cat# 24948). A total
of 50 µL of equilibrated protein A/G agarose (SCBT, Dallas, TX, USA, cat# sc-2003) was incubated with
either mouse anti-NEK1 antibody or mouse IgG antibody at 4 ◦ C for 4 h with rotation. A total of 500 µg
of protein lysate was added to the reaction and incubated overnight at 4 ◦ C. Beads were washed thrice
and eluted with 25 µL of 2X SDS-Laemmli buffer, and the entire volume was loaded into SDS-PAGE
gel for WB analysis.
2.6. Generation of NT1 NEK1 Knockout (KO) Cells Lines
NT1 NEK1 KO clones were generated by lentiviral infection using NEK1 CRISPR gRNA
(AAGGAGAGAAGTTGCTGTAT) cloned into pLentiCRISPR V2 vector backbone from Genscript
(Piscataway, NJ, USA). Lentivirus containing NEK1 CRISPR gRNA was packaged using HEK293T
cells. NT1 cells were infected with lentivirus using polybrene transfection reagent following standard
protocol. After 72 h of infection, cells were supplemented with fresh media and selected with 1–2 µg/mL
of puromycin for 10 days. To generate a single clonal population of NEK1 KO cells, we seeded 1–2 cells
per well in a 96-well plate and grew them until confluency, and then transferred them to a bigger
dish for expansion. KO efficiency was measured by Western blotting (WB) using anti-NEK1 mouse
antibody from Santa Cruz Biotechnology (Dallas, TX, USA, cat# sc-398813).
2.7. Protein Purification
Recombinant His-tagged full-length MK5 and His-tagged NEK1 N-terminal-truncated proteins
(NEK1∆CT) were purified by affinity chromatography. Both MK5 and NEK1∆CT were transformed
into Rosetta2 DE3 strain [23]. Expression of His-MK5 was induced with 1mM Isopropyl βd-1-thiogalactopyranoside (IPTG) at 37 ◦ C for 3–4 h, and His-NEK1∆CT expression was induced with
0.5 mM IPTG overnight at 25 ◦ C. Bacteria were pelleted down; dissolved in buffer containing 50 mM
sodium phosphate (Na2 HPO4 + NaH2 PO4 ) of pH 8.0, 300 mM NaCl, 20 mM imidazole, and 1mM
phenylmethylsulfonyl fluoride (PMSF); and lysed by sonication. Supernatants were incubated with
Ni-NTA agarose (Qiagen, cat# 30210), and protein was eluted in buffer containing 50 mM sodium
phosphate (Na2 HPO4 + NaH2 PO4 ) of pH 8.0, 300 mM NaCl, and 250 mM imidazole. Eluted proteins
were dialyzed overnight at 4 ◦ C using dialysis buffer containing 20 mM sodium phosphate (Na2 HPO4
+ NaH2 PO4 ) of pH 7.7, 1 M NaCl, 10 mM β-mercaptoethanol, 0.5 mM ethylenediaminetetraacetic acid
(EDTA) of pH 8.0, and 5% glycerol. After the dialysis, protein samples were run in SDS-PAGE gel to
check their purity and correct molecular weight.
2.8. ADP Hunter Assay
ADP hunter assays were conducted to determine the catalytic activity of the purified kinases by
the fluorescence detection of ATP to ADP conversion using an ADP Hunter Plus Assay kit (Eurofins,
DeSoto, TX, USA, cat# 90-0083). Increasing amount of purified recombinant NEK1 or MK5 were
incubated with either dephosphorylated α-casein (substrate for NEK1, source: Sigma-Aldrich, St.
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Louis, Missouri, USA, cat# C8032) or purified recombinant HSP27 (substrate for MK5, source: Abcam,
Cambridge, MA, USA, cat# ab48740). The manufacturer provided kinase buffer, and 50 µM of ATP
was added to the reaction, incubating the reaction at 30 ◦ C for 30 min. Afterwards, reagent A and B
were added sequentially, incubating the reaction at room temperature for 30 min. Stop solution was
added and fluorescence intensity signal was measured at 530/590 nm excitation/emission wavelength.
ADP concentration was determined by the standard curve through the serial dilutions of the ADP
standards provided with the kit.
2.9. In Vitro Kinase Assay
In vitro kinase (IVK) assays were performed using purified recombinant proteins, kinase buffer,
ATP, and/or [γ-32 P] ATP. Purified recombinant GST-tagged YAP1 (Novus Biologicals, cat# Centennial,
CO, USA, H00010413-P01) was incubated with either purified recombinant His-NEK1∆CT or purified
recombinant His-tagged MK5. Kinase buffer (10X) contains 10 mM Tris-Cl of pH 7.5, 10 mM MgCl2 ,
10 mM dithiothreitol (DTT), and 10 mM ATP. For radioactive IVK assays, we added 10µCi of radiolabeled
[γ-32 P] ATP purchased from Perkin Elmer (cat# BLU002H250UC). The reactions were incubated for
30 min at 30 ◦ C and subsequently were separated by SDS-PAGE, stained with Coomassie Brilliant Blue,
and exposed to X-ray film for 72 h. For mass spectrometric (MS) analysis, YAP1 bands were excised
after Coomassie staining and sent to the Kentucky MS facility.
2.10. Identification of YAP1 Phosphorylation by Mass Spectrometry
The band corresponding to YAP1 was excised and subjected to dithiothreitol reduction,
iodoacetamide alkylation, and in-gel chymotrypsin digestion. Peptides were extracted, concentrated,
and subjected to LC–MS/MS analysis at the University of Kentucky Proteomics Core Facility, as
previously reported [32]. Briefly, LC–MS/MS analysis was performed using an LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled with an Eksigent Nanoflex cHiPLC
system (Eksigent, Dublin, CA, USA) through a nano-electrospray ionization source. The peptide
samples were separated with a reversed-phase cHiPLC column (75 µm × 15 cm) at a flow rate of
300 nL/min. Mobile phase A was water with 0.1% (v/v) formic acid, while B was acetonitrile with
0.1% (v/v) formic acid. The data-dependent acquisition method consisted of an Orbitrap MS scan
(250–1800 m/z) with 60,000 resolution for parent ions, followed by MS/MS for fragmentation of the 10
most intense multiple charged ions. The LC–MS/MS data were submitted to a local Mascot server for
MS/MS protein identification via Proteome Discoverer (version 1.3, Thermo Fisher Scientific, Waltham,
MA, USA). Typical parameters used in the Mascot MS/MS ion search were chymotrypsin digestion
with a maximum of two miscleavages; 10 ppm precursor ion and 0.8 Da fragment ion mass tolerances;
and dynamic modifications, including cysteine carbamidomethylation, methionine oxidation, and
serine/threonine/tyrosine phosphorylation. The identified phosphorylation sites were illustrated with
relevant b and/or y ions labeled.
2.11. Western Blotting
Cells were collected and lysed by sonication in 1X RIPA lysis buffer. Protein concentration was
determined using a Pierce BCA protein assay kit (Thermo Scientific, cat# 23225, Waltham, MA, USA).
Samples from the lysate or co-IP or IVK assays were separated by SDS-PAGE gels and transferred
to polyvinylidene fluoride (PVDF) membrane. The membrane was blocked in 5% non-fat dry milk
for 1 h at room temperature and incubated with primary antibodies overnight at 4 ◦ C. Afterwards,
HRP-conjugated secondary antibodies were used to incubate the blots for 1 h at room temperature,
and finally the specific proteins were detected by chemiluminescence using ECL substrates (Thermo
Scientific, Waltham, MA, USA, cat# 32106) or by colorimetry using Opti-4CN substrate kit (Biorad, cat#
1708235, Waltham, MA, USA). The membrane was visualized by Biorad chemidoc imaging system
(Biorad, Hercules, CA, USA, cat# 12003154). Densitometric quantifications of each blot in arbitrary
units relative to the loading control are shown in Figure S5.
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2.12. Real-time Quantitative PCR (RT-qPCR)
Total RNA was isolated using a RNeasy RNA isolation minikit (Qiagen, cat# 74104, Germantown,
MD, USA) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized
using 1µg of RNA/reaction using ProtoScript First Strand RNA synthesis reverse transcriptase and
oligo (dT) primers (New England Biolab, cat# E6300L, Ipswich, MA, USA). qPCR was conducted
using iQ SYBR green supermix (Biorad, cat# 1708880, Des Plaines, IL, USA) and Bio-Rad CFX96 Fast
Real-Time PCR Systems. Gene expression changes were determined by ∆∆Ct relative quantification
method. GAPDH mRNA was used as an internal control. All values are presented as mean ± standard
error mean (SEM).
2.13. Bioinformatics Analysis
mRNA expression analyses of TCGA patient datasets were conducted using the UALCAN online
platform [33]. Oncoprints of the NEK1 and YAP1 protein level of at least more than 0.5-fold increase
was generated using Cbioportal [34] from The Cancer Genome Atlas (TCGA-firehose legacy) datasets.
Proteomic level of NEK1 and YAP1 based on the immunohistochemistry (IHC) analysis in different
cancers were determined using the Human Protein Atlas [35] database. Representative IHC images of
high-grade prostate adenocarcinoma (PRAD) and metastatic head and neck squamous cell (HNSC)
carcinoma were also obtained from the Human Protein Atlas database. Volcano plot of gene enrichment
correlated with NEK1 upregulation of TCGA (firehose legacy) head and neck cancer study was
generated using the cBIOPORTAL web tool.
3. Results
3.1. NEK1 Regulated the Stability of YAP
We have previously reported that androgen deprivation in LNCaP cells results in a strong increase
in expression of TLK1B. This increase is mTOR-dependent and suppressible with rapamycin [24]. Similar
results were obtained with TRAMP-C2 cells [24], and more recently in a AR+/PDX adenocarcinoma
model (NSG-TM00298 [25]). This is apparently a critical survival mechanism of AS-PCa cells that
implement a DDR in order to arrest in G1 upon androgen deprivation-like treatment with bicalutamide
(BIC) [36]. We have recently attributed the probable mechanisms causing this DDR activation to the
role played by the AR as a replication licensing factor [37] in combination with the increased expression
of TLK1B, and resulting activation of the NEK1>ATR>Chk1 axis [24], which is a key target of TLK1 [23].
Additional work from our lab suggested that this may be a conserved nexus in other cellular models,
in the TRAMP mice, and probably in many patients, since the specific activating phosphorylation of
NEK1 by TLK1 correlates with the Gleason score [25]. While the significance of the cell cycle arrest
upon unfavorable growth conditions (androgen deprivation therapy, ADT) seems clear in order to
avoid mitotic catastrophe, it is still unclear how AS-PCa cells eventually adapt to ADT and reprogram
to become AI (CRPC progression). Interestingly, we have previously noticed that when LNCaP cells
were stably transfected with a wt-NEK1 expression vector, they rapidly (less than 1 week) became
tolerant to BIC and resumed growth to form AI colonies [24]. However, this did not happen when
we expressed the hypoactive T141A-NEK1 variant [23] that cannot be phosphorylated/activated by
TLK1, while these cells also remained AS when injected as xenografts [24]. The rapid resumption of
growth of LNCaP-NEK1 cells in the presence of anti-androgen (BIC) could not be readily explained
by the implementation of the pro-survival DDR checkpoint, suggesting that NEK1 also promotes the
AI conversion. On the basis of a review of the literature (see the Introduction), we suspected that
NEK1 may affect the Hippo pathway, and thus we carried out a Western blotting (WB) analysis of
YAP expression in LNCaP cells overexpressing wt-NEK1 or NEK1-T141A variant. The cells were
also treated or not treated with BIC and thioridazine (THD), which is a rather specific inhibitor of
TLKs [38]. In Figure 1A (quantitation in Figure S5), we show that overexpression of the NEK1-T141A
variant results in reduced levels of YAP (lane 1 vs. 5), along with evidence of an elevated cleaved
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interacted
withwith
NEK1
and and
waswas
enriched
upon
coco-immunoprecipitation.
TLK1
inhibition
with
µMTHD
THDdid
didnot
notaffect
affectNEK1
NEK1 interaction
interaction with
with YAP,
YAP,
immunoprecipitation. TLK1
inhibition
with
1010µM
and
andthus
thusthe
thestate
stateof
ofNEK1
NEK1kinase
kinaseactivity
activitydid
did not
not affect
affectYAP
YAPbinding.
binding.(C)
(C) The
The expression
expressionof
of YAP
YAPwas
was
decreased
NT1
cellscells
treated
with two
inhibitorsinhibitors
of TLK (THD
and J54),
withand
a corresponding
decreasedinin
NT1
treated
withdifferent
two different
of TLK
(THD
J54), with a
increase
in CL-YAP
products.
(D) Expression
of (D)
several
typical YAP
target genes
in YAP
LNCaP
cellsgenes
treated
corresponding
increase
in CL-YAP
products.
Expression
of several
typical
target
in
with
THD.
LNCaP cells treated with THD.

We
Wealso
alsoshow
showthat
thatNEK1
NEK1interacted
interacted with
with YAP,
YAP,as
asititwas
wasenriched
enrichedby
byco-IP,
co-IP,and
andtheir
theirassociation
association
was
not
altered
by
THD
(Figure
1B,
top
panel;
quantitation
in
Figure
S5),
indicating
that
was not altered by THD (Figure 1B, top panel; quantitation in Figure S5), indicating that the
the NEK1
NEK1
kinase
activity
was
independent
of
its
ability
to
interact
with
YAP.
As
we
previously
reported
kinase activity was independent of its ability to interact with YAP. As we previously reported [23],
[23],
the
thesame
sameco-IP
co-IPalso
alsobrought
broughtdown
downTLK1,
TLK1,and
andTHD
THDdid
didnot
not affect
affecttheir
theirinteraction
interaction(Figure
(Figure1B,
1B,bottom
bottom
panel;
panel; quantitation
quantitation in
in Figure
Figure S5).
S5). There
There is
is aa possibility
possibility that
that in
in cells,
cells, NEK1,
NEK1, TLK1,
TLK1, and
and YAP
YAP are
are in
inaa
complex,
or
that
NEK1
interacts
independently
with
TLK1
and
YAP.
In
either
case,
TLK1
was
not
complex, or that NEK1 interacts independently with TLK1 and YAP. In either case, TLK1 was not
found
foundto
tointeract
interactdirectly
directlywith
withYAP
YAP[23].
[23].
To
confirm
the
effect
of
inhibition
To confirm the effect of inhibitionof
ofthe
theTLK1>NEK1
TLK1>NEK1axis
axis on
on the
the expression
expression of
of YAP
YAPin
in aa different
different
PCa
cell
line,
we
treated
Neo-TAg1
(NT1)
with
two
different
inhibitors
of
TLK1:
THD
PCa cell line, we treated Neo-TAg1 (NT1) with two different inhibitors of TLK1: THDor
orJ54.
J54. This
This

resulted in a reduction of YAP level and appearance of a set of cleavage products (Figure 1C;
quantitation in Figure S5).
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resulted in a reduction of YAP level and appearance of a set of cleavage products (Figure 1C; quantitation
NEK1
KO in NeoTag1 Cells Resulted in Reduced YAP Levels and Expression of Several of Its Target
in3.2.
Figure
S5).
Genes
3.2. NEK1 KO in NeoTag1 Cells Resulted in Reduced YAP Levels and Expression of Several of Its Target Genes
Consistent with our initial observations that NEK1 activity is critical for YAP stabilization, we
Consistent
our initial
that
NEK1 in
activity
is critical forKO
YAPofstabilization,
we
found that YAPwith
expression
wasobservations
concomitantly
reduced
CRISPR-mediated
NEK1 in the PCa
found
that
YAP
expression
was
concomitantly
reduced
in
CRISPR-mediated
KO
of
NEK1
in
the
PCa
line NT1 (Figure 2A; quantitation in Figure S5). Likewise, the expression of several YAP target genes
line
NT1
(Figure
2A;Twist1)
quantitation
in Figure
S5). Likewise,
the expression
of several
genes
(e.g.,
CTGF,
Zeb1,
that drive
Epithelial
to Mesenchymal
Transition
(EMT)YAP
and target
invasiveness
(e.g.,
CTGF,
Zeb1,
Twist1)
that
drive
Epithelial
to
Mesenchymal
Transition
(EMT)
and
invasiveness
of
of these cells was suppressed in all the positive NEK1 KO clones (Figure 2B). Conversely, inhibition
these
cellswith
wasTHD,
suppressed
the positive
KO clones
inhibition
of
of TLK1
which in
weall
showed
leads NEK1
to reduced
NEK1 (Figure
activity 2B).
[23],Conversely,
can inhibit cell
migration
TLK1
with THD,of
which
we showed
leads
NEK1
activityN-cadherin,
[23], can inhibit
cellSnail3,
migration
via suppression
EMT-related
genes
suchtoasreduced
Claudin1,
E-cadherin,
Twist1,
Slug,
via
suppression
EMT-related
such
as Claudin1,
E-cadherin,
Twist1,
Slug,
FOXC2,
MMP3,ofand
MMP9 ingenes
Hepato
Cellular
Carcinoma
(HCC)N-cadherin,
cells [39]. We
nowSnail3,
suggest
this
FOXC2,
MMP3,
and from
MMP9
in Hepato
Cellular
Carcinoma
(HCC) cells
WeNEK1
now (activity)
suggest this
observation
derives
reduction
of YAP
expression
concomitant
with[39].
loss of
due
observation
derives
from
reduction
of YAPinexpression
loss ofS5)
NEK1
due to
to inhibition
of TLK.
In fact,
we showed
Figure 2Cconcomitant
(quantitationwith
in Figure
that(activity)
YAP expression
inhibition
of
TLK.
In
fact,
we
showed
in
Figure
2C
(quantitation
in
Figure
S5)
that
YAP
expression
was
was reduced in LNCaP cells treated with THD, while conversely, pYAP(S127), which is a phosphoreduced
LNCaP
treated withdegradation,
THD, while was
conversely,
pYAP(S127), which is a phospho-degron
degron in
leading
to cells
its proteasomal
elevated.
leading to its proteasomal degradation, was elevated.

Figure
Figure2.2.(A)
(A)CRISPR/Cas9-mediated
CRISPR/Cas9-mediatedloss
lossofofNEK1
NEK1resulted
resultedininreduced
reducedlevels
levelsof
ofYAP
YAPprotein,
protein,possibly
possibly
due
to
instabilization
(EV
=
empty
vector).
(B)
Expression
of
several
typical
YAP
target
genes
is reduced
due to instabilization (EV = empty vector). (B) Expression of several typical YAP target
genes is
inreduced
NEK1 KO
clones.
mRNA was
used
as used
an internal
control.control.
(C) Treatment
of LNCaP
cells
in NEK1
KOGAPDH
clones. GAPDH
mRNA
was
as an internal
(C) Treatment
of LNCaP
with
THD,
a
specific
inhibitor
of
TLKs,
resulted
in
reduced
YAP
protein
level
and
conversely
in
its
S127in
cells with THD, a specific inhibitor of TLKs, resulted in reduced YAP protein level and conversely
hyperphosphorylation.
(D) Reduction
TLK1 expression
viaexpression
(short hairpin)
transfection
led
its S127 hyperphosphorylation.
(D) ofReduction
of TLK1
via shRNA
(short hairpin)
shRNA
totransfection
loss of pNEK1-T141.
led to loss of pNEK1-T141.

In order to confirm with a genetic approach that the inhibition of TLK1 results in suppression of
In order to confirm with a genetic approach that the inhibition of TLK1 results in suppression of
the pathway that leads to activation of NEK1 and subsequent stabilization of YAP, we knocked down
the pathway that leads to activation of NEK1 and subsequent stabilization of YAP, we knocked down
TLK1 with shRNA in HeLa cells. Effective knockdown of TLK1 was achieved in a dose-dependent
TLK1 with shRNA in HeLa cells. Effective knockdown of TLK1 was achieved in a dose-dependent
manner with the shRNA (Figure 2D; quantitation in Figure S5), and importantly, activated NEK1
manner with the shRNA (Figure 2D; quantitation in Figure S5), and importantly, activated NEK1
levels, i.e., pNEK1(T141) were similarly suppressed. This suggests that at least in these cells, TLK1 is
levels, i.e., pNEK1(T141) were similarly suppressed. This suggests that at least in these cells, TLK1 is
the principal kinase responsible for the phosphorylation and activation of NEK1—note that the T141
the principal kinase responsible for the phosphorylation and activation of NEK1—note that the T141
residue resides in the kinase domain of the protein adjacent to the activation loop [40] that we have
residue resides in the kinase domain of the protein adjacent to the activation loop [40] that we have
previously shown to be important for NEK1 kinase activity [23].
previously shown to be important for NEK1 kinase activity [23].
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3.3. NEK1 Phosphorylated YAP In Vitro on Several Residues
order
to determineYAP
if NEK1
could
3.3. In
NEK1
Phosphorylated
In Vitro
on phosphorylate
Several ResiduesYAP in vitro, we first purified a recombinant
His-tagged NEK1-NT fragment spanning nearly half of the entire protein (total NEK1 protein = 1258
In order to determine if NEK1 could phosphorylate YAP in vitro, we first purified a recombinant
AA, Singh et al. (2017) [ref 23]) following standard protocol and determined its catalytic activity using
His-tagged NEK1-NT fragment spanning nearly half of the entire protein (total NEK1 protein = 1258
dephosphorylated α-casein by ADP Hunter assay (Figure 3A,B, see the Section 2). ADP hunter assay
AA, Singh et al. (2017) [ref 23]) following standard protocol and determined its catalytic activity using
revealed that our lab-purified truncated NEK1 is catalytically active, as the incubation of increasing
dephosphorylated α-casein by ADP Hunter assay (Figure 3A,B, see the Section 2). ADP hunter assay
amounts of NEK1 resulted in corresponding ATP to ADP conversion (Figure 3B). Afterwards, we
revealed that our lab-purified truncated NEK1 is catalytically active, as the incubation of increasing
carried out a preliminary in vitro kinase (IVK) reaction by incubating purified recombinant Hisamounts of NEK1 resulted in corresponding ATP to ADP conversion (Figure 3B). Afterwards, we
tagged NEK1 with purified recombinant GST-YAP (Novus Biologicals) and [γ-32P] ATP. For
carried out a preliminary in vitro kinase (IVK) reaction by incubating purified recombinant His-tagged
comparison, we also carried out the IVK reaction using recombinant32 MK5, which was recently
NEK1 with purified recombinant GST-YAP (Novus Biologicals) and [γ- P] ATP. For comparison, we
reported to be a novel YAP1 kinase [41]. The purity of all recombinant proteins is shown in the
also carried out the IVK reaction using recombinant MK5, which was recently reported to be a novel
Coomassie Blue-stained SDS/PAGE, and the autoradiography of the gel is shown above it (Figure 3C;
YAP1 kinase [41]. The purity of all recombinant proteins is shown in the Coomassie Blue-stained
quantitation in Figure S5). Notably, NEK1 was capable of strongly phosphorylating YAP, even when
SDS/PAGE, and the autoradiography of the gel is shown above it (Figure 3C; quantitation in Figure S5).
small amounts were used (see stained gel). In contrast, MK5 (even in high amount) was a very weak
Notably, NEK1 was capable of strongly phosphorylating YAP, even when small amounts were used
kinase for YAP, if at all, although it was clearly highly active since it was capable of auto(see stained gel). In contrast, MK5 (even in high amount) was a very weak kinase for YAP, if at all,
phosphorylation (see autoradiogram) and when tested with ADP Hunter reagent.
although it was clearly highly active since it was capable of auto-phosphorylation (see autoradiogram)
and when tested with ADP Hunter reagent.

Figure 3. (A) Expression and purification of His-NEK1 kinase domain (NEK1∆CT). (B) NEK1∆CT was
Figure
3. (A) Expression
and purification
of His-NEK1
kinase domain
(NEK1∆CT).
(B) NEK1∆CT
catalytically
active and ATP/ADP
conversion
(kinase activity)
was linear
with the enzyme
amount.was
(C)
catalytically
active
and
ATP/ADP
conversion
(kinase
activity)
was
linear
with
the
enzyme
32 P] ATP.
In vitro phosphorylation reactions of YAP using His-NEK1 and MK5 kinases in presence of [γ-amount.
(C)
reactions
of YAP
using and
His-NEK1
and MK5
kinases in presence
of [γ(D)In
Invitro
vitro phosphorylation
phosphorylation of
YAP using
His-NEK1
MK5 kinases
for preparative
isolation for
MS
32P] ATP. (D) In vitro phosphorylation of YAP using His-NEK1 and MK5 kinases for preparative
determination of phosphopeptides. (E) His-NEK1 also phosphorylated YAP on Tyr, as demonstrated
isolation
for MS determination
of phosphopeptides. (E) His-NEK1 also phosphorylated YAP on Tyr,
by immunoreactivity
with pY antibody.
as demonstrated by immunoreactivity with pY antibody.

The IVK reactions were repeated with greater amounts of proteins for preparative isolation for MS
The for
IVKassignment
reactions were
with greater
amounts
of proteins
preparative
isolation
for
analysis
of therepeated
phosphorylated
residues
(Figure
3D). The for
bands
corresponding
to YAP
MS
analysiswith
for assignment
phosphorylated
(Figureof3D).
The bands corresponding
to
incubated
NEK1, MK5,oforthe
mock
were excised. residues
Determination
the phosphorylated
peptides and
YAP
incubated
with
NEK1,
MK5,
or
mock
were
excised.
Determination
of
the
phosphorylated
assignment of the phospho-amino acids were carried out at the University of Kentucky Proteomics
peptides
andYAP
assignment
of thedigested
phospho-amino
acids were and
carried
out at with
the University
of Kentucky
facility. The
bands were
with chymotrypsin
analyzed
an LTQ-Orbitrap
mass
Proteomics
facility.
The
YAP
bands
were
digested
with
chymotrypsin
and
analyzed
with
an
LTQspectrometer. MS datasets were searched with MASCOT against a custom database containing only
Orbitrap
massand
spectrometer.
MS datasets
searched
with
MASCOT
against
a custom
database
human YAP1
NEK1. A synopsis
of thewere
results
is that (1)
when
searched
against
YAP1 and
NEK1,
containing
onlydetected
human YAP1
and
NEK1. (well
A synopsis
of the
is that
when peptide
searchedcoverage
against
only YAP was
in these
samples
separated
onresults
the gel),
with(1)
43–49%
YAP1
and NEK1,
YAP was(2)
detected
in phosphorylation
these samples (well
thedetected
gel), with
and protein
scoresonly
of 2573-3321;
potential
sitesseparated
S163/S164on
were
in 43–49%
all three
peptide
andthe
protein
of 2573-3321;
potential
sites phosphorylated
S163/S164 were
samplescoverage
(including
YAP1scores
no kinase
sample), (2)
which
can bephosphorylation
explained as a basal
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detected in all three samples (including the YAP1 no kinase sample), which can be explained as a
residue
of recombinant YAP
isolated
from wheatYAP
germ;
and (3)from
six unique
were
basal phosphorylated
residue
of recombinant
isolated
wheat phosphorylation
germ; and (3) sixsites
unique
detected
in
the
YAP_NEK1
sample:
T83,
T361,
S366,
S388,
S406,
Y407,
or
T493
(Figure
4
and
Figures
phosphorylation sites were detected in the YAP_NEK1 sample: T83, T361, S366, S388, S406, Y407, or
S1–S4;
S1).
However,
unique
phosphorylation
site
was detected in
the
YAP_MK5
T493 Table
(Figures
4 and
S1–S4; no
Table
S1). However,
no unique
phosphorylation
site
was
detected sample,
in the
YAP_MK5
sample,
which
we now
suggest isYAP
not an
authentic
YAP kinase.
in the
paper
which
we now
suggest
is not
an authentic
kinase.
Interestingly,
inInterestingly,
the paper that
purported
thatas
purported
MK5 as
an kinase,
important
kinase,
authors
not report
theytoattempted
MK5
an important
YAP
theYAP
authors
didthe
not
reportdid
whether
theywhether
attempted
verify that
to verify
that MK5 can phosphorylate
YAP
inthey
vitro,identify
nor didthe
they
identify the phosphorylation
MK5
can phosphorylate
YAP in vitro, nor
did
phosphorylation
target in vivotarget
[41]. In
in vivo
In Figure
we present
an example
of data
identifying
andwe
T493,
which assume
we currently
Figure
4, [41].
we present
an4,example
of data
identifying
Y407
and T493,Y407
which
currently
are the
assume
are
the
most
interesting.
most interesting.

Figure 4. MS/MS spectra demonstrating the phosphorylation sites at T493 (A) and S406/Y407 (B) as
Figure 4.ofMS/MS
spectra
demonstrating the phosphorylation sites at T493 (A) and S406/Y407 (B) as
examples
LC–MS/MS
determinations.
examples of LC–MS/MS determinations.

All of the phosphorylated residues listed in Table S1 have been reported in MS studies in cells,
All of
the report
phosphorylated
residues
listed
in Table
S1 have
been reported
MS studies
in cells,
according
to the
of Phosphosite
Plus,
except
for S406
(putative)
and T493,inwhich,
as such,
are the
according
to
the
report
of
Phosphosite
Plus,
except
for
S406
(putative)
and
T493,
which,
as
such,
first report of phosphorylation of these residues specifically by NEK1. The phosphorylation of are
Y407
the first report of phosphorylation of these residues specifically by NEK1. The phosphorylation of
(putative)
should not be surprising, since NEK1 is a dual specificity kinase that was originally identified
Y407 (putative) should not be surprising, since NEK1 is a dual specificity kinase that was originally
as a tyrosine kinase [42]. Note that although the MS/MS spectrum could not distinguish the exact

the exact phosphorylation site at S406 or Y407, a phospho-Tyr Western blot (Figure 3E; quantitation
in Figure S5) supported the conclusion that Y407 (the only identified pTyr in the MS analysis) was
phosphorylated. It is also noteworthy that the NEK1 protein was also phosphorylated on Tyr (Figure
3E), as we previously reported that it is in fact auto-phosphorylated on Y315 [23], confirming the
specificity of the antiserum.
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3.4. Bioinformatic Studies Suggest NEK1 Mediated Stabilization of YAP1 in Different Cancers

phosphorylation
site mRNA
at S406 or
Y407, a phospho-Tyr
blotin
(Figure
3E;adenocarcinoma
quantitation in Figure
S5)
We analyzed
expression
of both NEK1Western
and YAP1
prostate
(PRAD)
supported
theand
conclusion
that Y407 cell
(the (HNSC)
only identified
pTyr in
the MSfrom
analysis)
wasdatasets
phosphorylated.
and head
neck squamous
carcinoma
patients
TCGA
using theIt
UALCAN
onlinethat
platform.
In PRAD,
alteration inonmRNA
expression
was
is also
noteworthy
the NEK1
protein no
wassignificant
also phosphorylated
Tyr (Figure
3E), asof
weNEK1
previously
observed
while YAP1 mRNA level
was consistently
downregulated
with
to the
reported
that(Figure
it is in 5A),
fact auto-phosphorylated
on Y315
[23], confirming
the specificity
ofrespect
the antiserum.
tumor Gleason score (Figure 5B). However, reverse phase protein array (RPPA)-based protein
3.4.profiling
Bioinformatic
Studies
YAP1 inrevealed
Differentupregulation
Cancers
of NEK1
and Suggest
YAP1 inNEK1
PRADMediated
patientsStabilization
from TCGAofdatasets
of YAP1
level (Figure 5D), but no change in NEK1 protein level (Figure 5C). In addition, proteomic analysis
We analyzed mRNA expression of both NEK1 and YAP1 in prostate adenocarcinoma (PRAD) and
based on immunohistochemistry (IHC) data from the Human Protein Atlas web server revealed a
head and neck squamous cell (HNSC) carcinoma patients from TCGA datasets using the UALCAN
higher protein level of NEK1 and YAP1 in high-grade PRAD patients (Figure 5G,H). Representative
online platform. In PRAD, no significant alteration in mRNA expression of NEK1 was observed
IHC analysis revealed intense staining of both NEK1 and YAP1 in high-grade PRAD compared to
(Figure 5A), while YAP1 mRNA level was consistently downregulated with respect to the tumor
normal prostate tissue (Figure 5I). This supports our hypothesis of NEK1 implication in YAP1 protein
Gleason score (Figure 5B). However, reverse phase protein array (RPPA)-based protein profiling
stabilization/accumulation in advanced PCa, despite YAP1 transcript downregulation.
of NEK1 and YAP1 in PRAD patients from TCGA datasets revealed upregulation of YAP1 level
Similarly, in head and neck squamous cell carcinoma (Figure 5F), glioblastoma, and other
(Figure
5D),
but not
no change
NEK1
level (Figure
5C). In of
addition,
proteomic
analysis
cancers
(data
shown), in
there
wasprotein
no significant
upregulation
YAP1 mRNA
expression;
based
on
immunohistochemistry
(IHC)
data
from
the
Human
Protein
Atlas
web
server
revealed
nonetheless, YAP1 protein level was elevated in high-grade metastatic tumors (Figure 5). Moreover, a
higher
level of NEK1
andsignificantly
YAP1 in high-grade
(Figure
geneprotein
set enrichment
analysis
correlatedPRAD
NEK1patients
expression
with5G,H).
severalRepresentative
YAP1 target
IHC
analysis
revealed
intense
staining
of
both
NEK1
and
YAP1
in
high-grade
genes such as Zeb1, BirC2, BirC6, Ankrd11, and ARID1B (Figure 5J; Table 1). PRAD
Overall,compared
these datato
normal
prostate
(Figure
5I).
Thisbysupports
hypothesis
of NEK1 rate
implication
in YAP1
protein
suggest
NEK1tissue
increases
YAP1
level
reducingour
YAP1
protein turnover
in different
cancers.
stabilization/accumulation in advanced PCa, despite YAP1 transcript downregulation.

Figure 5. Gene expression of (A) NEK1 and (B) YAP1 of prostate adenocarcinoma (PRAD) patients
Figure 5. Gene expression of (A) NEK1 and (B) YAP1 of prostate adenocarcinoma (PRAD) patients
on the basis of the Gleason score extracted from The Cancer Genome Atlas (TCGA) datasets using
on the basis of the Gleason score extracted from The Cancer Genome Atlas (TCGA) datasets using the
the UALCAN web tool. OncoPrint representation of the protein level alteration of (C) NEK1 and (D)
UALCAN web tool. OncoPrint representation of the protein level alteration of (C) NEK1 and (D)
YAP1 of PRAD patients by reverse phase protein array (RPPA) extracted from TCGA (firehose legacy)
YAP1 of PRAD patients by reverse phase protein array (RPPA) extracted from TCGA (firehose legacy)
datasets using cBIOPORTAL online platform. Gene expression of (E) NEK1 and (F) YAP1 in head and
datasets using cBIOPORTAL online platform. Gene expression of (E) NEK1 and (F) YAP1 in head and
neck squamous cell (HNSC) patients on the basis of the tumor grade extracted from TCGA datasets
using the UALCAN web tool. Percentage of patients of different types of cancer with higher level of (G)
NEK1 and (H) YAP1 on the basis of immunohistochemistry (IHC) staining generated using the Human
Protein Atlas database. Staining intensity correlated with the color code. Deeper color represents
high staining intensity. (I) Representative IHC images of NEK1 and YAP1 of high-grade PRAD (top
panel) and metastatic HNSC samples (bottom panel). (J) Volcano plot of gene enrichment analysis
based on NEK1 overexpression in HNSC patients extracted from TCGA (firehose legacy) datasets using
cBIOPORTAL online platform. * represents p < 0.05, ** represents p < 0.005, and *** represents p <
0.0005. All comparisons were with the normal tissue.
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Similarly, in head and neck squamous cell carcinoma (Figure 5F), glioblastoma, and other cancers
(data not shown), there was no significant upregulation of YAP1 mRNA expression; nonetheless, YAP1
protein level was elevated in high-grade metastatic tumors (Figure 5). Moreover, gene set enrichment
analysis significantly correlated NEK1 expression with several YAP1 target genes such as Zeb1, BirC2,
BirC6, Ankrd11, and ARID1B (Figure 5J; Table 1). Overall, these data suggest NEK1 increases YAP1
level by reducing YAP1 protein turnover rate in different cancers.
Table 1. Some of the YAP target genes significantly upregulated with NEK1 upregulation in head and
neck squamous cell (HNSC) carcinoma (TCGA, firehose legacy) analyzed using cBIOPORTAL.
Gene Name

Mean Log2 mRNA Expression ± SD in
NEK1-Overexpressed Group

p-Value

q-Value

Zeb1
Zeb2
Ankrd36B
Ankrd11
BirC2
BirC6
HoxB3
ARID1B
WSB2
CAT
ABCB1
PTX3

8.57 ± 1.00
8.80 ± 1.05
4.33 ± 0.93
11.55 ± 0.49
10.46 ± 0.96
11.13 ± 0.49
6.44 ± 2.11
10.84 ± 0.46
11.05 ± 0.45
10.01 ± 0.68
5.11 ± 1.45
5.33 ± 2.12

3.68 × 10−7
7.237 × 10−6
1.410 × 10−4
1.159 × 10−3
0.0187
3.91 × 10−12
0.0169
4.14 × 10−10
2.016 × 10−4
3.621 × 10−4
0.0111
1.994 × 10−4

5.153 × 10−6
6.617 × 10−5
8.367 × 10−4
4.984 × 10−3
0.0498
2.80 × 10−10
0.0458
1.57 × 10−8
1.136 × 10−3
1.872 × 10−3
0.0327
1.126 × 10−3

4. Discussion
During studies aimed at elucidating the process of ADT adaptation of AS PCa cell (initially in
LNCaP), which proceeds through a process of activating the DDR and increased activity of the kinases
TLK1B and NEK1 [11,24,25], we made the observation that overexpression of wt-NEK1, but not the
hypoactive NEK1-T141A variant that cannot be activated by TLK, resulted in a rapid adaptation
to bicalutamide and formation of AI colonies. From a review of the literature on the process of
AI conversion of LNCaP and other studies of CRPC progression, we suspected the involvement of
Hippo pathway deregulation and, in particular, YAP-driven gene expression (for a recent review,
see [43]). Moreover, Yim et al. reported that NEK1 can phosphorylate TAZ and regulates its turnover
rate [18]. Since YAP1 and TAZ are two highly homologous proteins that possess several conserved
phospho-residues, we set out to investigate the protein level of YAP in LNCaP overexpressing
wt-NEK1 and the T141A mutant in conjunction with a TLK inhibitor (THD) to suppress the activating
phosphorylation of NEK1. Interestingly, we observed an increased degradation of YAP in cells
overexpressing NEK1-T141A mutant or parental LNCaP treated with THD, in contrast to elevated level
of YAP (and no degradation) in cells that overexpress wt-NEK1 (Figure 1). Furthermore, treatment of
LNCaP cells with THD resulted in downregulated expression of several YAP-dependent transcripts
(Figure 1D). As an indication that this is in fact a general phenomenon in PCa, increased degradation
of YAP1 after inhibition of the TLK1>NEK1 axis with THD or J54 was independently verified in mouse
NT1 cells (Figure 1C). In addition, genetic depletion of NEK1 resulted in YAP1 loss and YAP1 target
gene downregulation in NT1 cells (Figure 2). It should be noted that YAP is a generally unstable protein
whose turnover rate is strongly regulated by multiple stabilizing [44] or de-stabilizing phosphorylation
events controlled by multiple kinases (see [19,20,26] for some reviews). Large tumor suppressor 1
and 2 (LATS1/2), the core kinases of the Hippo signaling pathway, can phosphorylate YAP1 on Ser127
residue, which creates a binding site for 14-3-3 proteins. The 14-3-3 binding of YAP leads to the
cytoplasmic sequestration of YAP [45,46]. Sequential phosphorylation by LATS1/2 on YAP Ser397
primes it for further phosphorylation by Casein Kinase CK1δ/ε on Ser400 and Ser403, which creates a
phosphodegron motif for (Skp Cullin F box) β-TrCP/SCF E3 ubiquitin ligase-mediated proteasomal
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degradation [47]. Recent findings also identify factors such as NR4A1 (nuclear receptor superfamily)
that regulate the 14-3-3 interaction with YAP1 and promote its ubiquitination and degradation [48].
Several other kinases independent of the Hippo pathway can regulate the stability of YAP1 protein. For
instance, nuclear Dbf2-related kinase (NDR1/2) can also phosphorylate YAP on Ser127 residue and can
promote its cytoplasmic retention, thereby negatively regulating YAP stability [49]. Evidence suggests
that the protein kinase B/AKT can also phosphorylate YAP on Ser127 residue, leading to binding of
14-3-3 and cytoplasmic retention [45]. In contrast, several members of the Src family of kinases such as
Src, Yes, and c-Abl can positively regulate YAP stability. c-Abl/Src/Yes are known to phosphorylate YAP
on Tyr357 residue, which results in the nuclear translocation and, hence, stabilization of YAP [44,50,51].
Moreover, Ras-associated factor isoform 1C (RASSF1C) is known to promote tyrosine phosphorylation
of YAP1 (Tyr357) through activated Src (pTyr416) and cause nuclear localization of YAP1 [52]. Similarly,
mitogen-activated protein kinases such as c-Jun-N-terminal kinases (JNK1/2) are also reported to be
YAP kinases that phosphorylate YAP on Ser317 and Thr362, promoting YAP nuclear translocation
and stabilization [53]. Thus, post-translational modifications such as phosphorylation determine YAP
turnover rate and activity.
Therefore, we propose the phosphorylation of Y407 as one potential mechanism of YAP stabilization
and increased transcriptional output, although the other 5-phosphorylation sites could be equally
important (Figure 4 and Figures S1–S4; Table S1). There are examples in YAP and TAZ where
phosphorylation of some residues impairs ubiquitination and subsequent proteasomal degradation, as
in one example, phosphorylation of S128 by NLK competed for the destabilizing LATS1-dependent
S127 phosphorylation [54]. However, we currently favor a pY407-related mechanism based on the
equivalent pY316 of TAZ, where it was shown that the phosphorylation of that residue, reportedly
by c-Abl, was necessary to mediate its interaction with the transcription factor NFAT5 [55]. This was
implicated in an inhibitory pathway of NFAT5—a major osmoregulatory transcription factor—during
hyperosmotic stress. Similarly, JNK1/2-mediated phosphorylation of YAP1 on Ser317 and Thr362
promotes YAP’s ability to bind and stabilize both pro-apoptotic p73 and pro-proliferative ∆Np63α in
different cell types [53,56]. We think that, likewise, pY407 promotes the interaction of YAP with some
of its transcriptional partners, and hence promotes its nuclear translocation, function, and stabilization,
away from cytoplasmic degradation. Importantly, while the phosphorylation of Y407 was identified in
proteomic studies [57], to our knowledge, the kinase responsible for it has not been reported.
Resistance to androgen deprivation therapy (ADT) promotes androgen-independent growth
and proliferation of PCa cells, which requires efficient DNA damage response (DDR) and repair
mechanisms, activation of compensatory signaling pathways, transcription factors, and co-factors to
drive castration resistance. Findings from our lab and others suggest that ADT activates the TLK1-NEK1
signaling pathway that promotes PCa progression by activating the DDR [11,24]. Hyper-activation of
NEK1 may also lengthen G2/M checkpoints, which provides the cells sufficient time to repair their
damaged DNA after ADT or radiation therapy [7,58]. However, DDR alone may not be able to induce
androgen-insensitive growth of PCa cells. Thus, we hypothesize that TLK1-NEK1 may be implicated
in some other signaling pathway, leading to AI growth. YAP1 is a major oncoprotein that drives many
different types of malignancies, including PCa [59], head and neck cancer [59], gastric cancer [60],
colon cancer [60], thyroid cancer [61], lung cancer [62], ovarian cancer [63], and liver cancer [64].
NEK1-mediated phosphorylation of YAP1 (most probably on Tyr407 and/or Thr493) may induce a
conformational change that counteracts the sequential phosphorylation by LATS1/2 and CK1δ/ε and
subsequently protects YAP from proteasomal degradation. Moreover, Tyr407 lies on the transcriptional
activation domain of YAP1, which may increase its interaction affinity to its assigned transcriptional
factors [65]. Ectopic YAP expression was reported to drive LNCaP cells from androgen-sensitive to
androgen-insensitive states [19]. Reducing the turnover rate will increase cellular accumulation of
YAP, which can enable its oncogenic properties to drive castration resistance by several mechanisms.
Previous studies reported that YAP can mediate PI (3)K-mTOR signaling and activate AKT [66–68].
Activation of mTOR will lead to enhanced translation of TLK1B that can, in turn, increase YAP1
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phosphorylation through TLK1-NEK1 nexus. This suggests a positive feed-forward mechanism for
YAP accumulation. Elevated YAP can also activate ERK that will promote cell proliferation in absence of
AR signaling. Kuser-Abali et al. reported that AR and YAP can interact, and this interaction contributes
to the switch from androgen-dependent to castration-resistant phenotype [27]. Overexpression of YAP
can also regulate the expression of AR target genes, including PSA, NKX3.1, PGC-1, and KLK2, which
suggests that YAP may control AR activity. YAP Tyr407 phosphorylation could increase the binding
affinity of AR and AR ligand-insensitive variant AR-V7, thus contributing to androgen refractory
growth of PCa cells. Therapy-induced YAP overexpression may also induce EMT activation by
upregulating EMT-specific genes. Increasing the stemness of PCa cells can be another mechanism
by which stabilized YAP can promote castration-resistant growth of PCa cells, which will further
contribute to chemo-resistance of cancer cells [69]. Our bioinformatics analyses also suggested a link
between NEK1 and YAP1 in different cancers (Figure 5). YAP1 protein level is abundant in high-grade
PCa tumors, despite the progressive downregulation of YAP1 mRNA expression. Other groups also
reported that YAP protein is positively correlated with the Gleason score, consistent with the findings
of our bioinformatics analysis [70]. We propose that the signaling of TLK1>NEK1-mediated YAP
phosphorylation and stabilization contributes not only to PCa progression, but also many other cancers.
Importantly, we found a correlation between increased phosphorylated NEK1(T141) in relation to the
Gleason score [25] and YAP1 protein expression, whereas the mRNA for YAP1 actually decreased
(Figure 5), consistent with our model of post-transcriptional protein stabilization.
5. Conclusions
YAP’s transcriptional activity and degradation is mainly regulated by phosphorylation through
several kinases dependent and independent of the Hippo pathway. Using small molecule inhibitors
against YAP cannot completely abolish YAP transcriptional activity and is not very effective in treating
YAP-driven cancers. Inhibitors such as verteporfin that can disrupt the YAP–TEAD interaction, but
still cannot result in complete inhibition, as YAP can bind with other transcription factors such as TEF,
SMADs, or TBX5. The majority of YAP kinases negatively regulate YAP by promoting its nuclear
egress or degradation; however, NEK1 is found to stabilize YAP protein by phosphorylating it on
several residues. Thus, targeting NEK1 or the TLK1–NEK1 axis can bring about therapeutic benefits in
the clinical management of YAP-driven malignancies.
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